4530 — Hisamitsu Pharmaceutical Co Balance Sheet
0.000.00%
- ¥312bn
- ¥189bn
- ¥156bn
- 95
- 45
- 89
- 91
Annual balance sheet for Hisamitsu Pharmaceutical Co, fiscal year end - February 28th, JPY millions except per share, conversion factor applied.
2021 February 28th | 2022 February 28th | 2023 February 28th | 2024 February 29th | 2025 February 28th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
Standards: | JAS | JAS | JAS | JAS | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 135,997 | 142,431 | 136,868 | 125,321 | 129,116 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 39,203 | 38,112 | 39,753 | 42,983 | 46,879 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 198,061 | 200,176 | 199,174 | 194,022 | 203,788 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 37,354 | 39,069 | 43,209 | 49,462 | 59,899 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 299,861 | 302,858 | 313,917 | 328,779 | 343,068 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 30,057 | 32,160 | 42,578 | 45,938 | 47,226 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 47,562 | 49,690 | 57,551 | 63,902 | 66,244 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 252,299 | 253,168 | 256,366 | 264,877 | 276,824 |
Total Liabilities & Shareholders' Equity | 299,861 | 302,858 | 313,917 | 328,779 | 343,068 |
Total Common Shares Outstanding |